- Conditions
- Melanoma, Renal Cell Carcinoma, Non Small Cell Lung Cancer, Urothelial Carcinoma, Triple Negative Breast Cancer, HR+/HER2- Breast Cancer, Gastric Cancer
- Interventions
- Dose Escalation Doublet: Combination of NKTR-214 + nivolumab, Dose Expansion Doublet: Combination of NKTR-214 + nivolumab, Schedule Finding Triplet: Combination of NKTR-214+ nivolumab+ ipilimumab, Dose Expansion Triplet: Combination of NKTR-214+ nivolumab+ ipilimumab
- Drug
- Lead sponsor
- Nektar Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 557 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2022
- U.S. locations
- 22
- States / cities
- La Jolla, California • Los Angeles, California • Stanford, California + 17 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 265–288
of 7,390
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Gram-negative Bacterial Infection
- Interventions
- Part A: Single Dose Ceftazidime-Avibactam, Cohorts 1-3, Part B: Multiple-dose Ceftazidime-Avibactam, Cohorts 1-3
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 0 Days to 88 Days
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 5
- States / cities
- Boston, Massachusetts • Durham, North Carolina • Salt Lake City, Utah
- Conditions
- Locally Advanced/Metastatic Solid Tumors
- Interventions
- HY-0102
- Drug
- Lead sponsor
- Shanghai HyaMab Biotech Co.,Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 3
- States / cities
- Orlando, Florida • Las Vegas, Nevada • Tyler, Texas
- Conditions
- Solid Tumor Malignancies
- Interventions
- Imetelstat Sodium (GRN163L)
- Drug
- Lead sponsor
- Geron Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 85 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2013
- U.S. locations
- 2
- States / cities
- Chicago, Illinois • Detroit, Michigan
- Conditions
- Rheumatoid Arthritis, Healthy Controls
- Interventions
- Blood Draw, Disease Activity (DAS-28) Assessment, Skeletal Muscle Mitochondrial Respiratory Capacity, Muscle Biopsy, Body Composition, Cardiopulmonary Exercise Test (CPET), Strength Testing, Questionnaires, Skeletal Muscle Biomechanical Property Assessment
- Other
- Lead sponsor
- Duke University
- Other
- Eligibility
- 25 Years to 75 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2023
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Non Small Cell Lung Cancer, Metastatic, Recurrent
- Interventions
- Lorlatinib, Ramucirumab
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 19 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 6
- States / cities
- Middletown, New Jersey • Montvale, New Jersey • Commack, New York + 3 more
- Conditions
- Dyslipidaemia
- Interventions
- AZD0780, Itraconazole, Carbamazepine, Midazolam, Ethinyl estradiol/levonorgestrel
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 59 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Brooklyn, Maryland
- Conditions
- Chemotherapy-induced Peripheral Neuropathy, Plasma Cell Myeloma
- Interventions
- VascuTherm5 vascular compression device
- Device
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 1
- States / cities
- Winston-Salem, North Carolina
- Conditions
- Endometrial Neoplasms, Ovarian Cancer, Solid Tumor, Head and Neck Cancer
- Interventions
- COM701 in combination with BMS-986207 and nivolumab.
- Drug
- Lead sponsor
- Compugen Ltd
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 9
- States / cities
- Chicago, Illinois • Baltimore, Maryland • Boston, Massachusetts + 6 more
- Conditions
- Lower Respiratory Tract Infection, Parainfluenza, Immunocompromised, COVID-19
- Interventions
- DAS181, Placebo, DAS181 COVID-19, DAS181 OL
- Drug
- Lead sponsor
- Ansun Biopharma, Inc.
- Industry
- Eligibility
- Not listed
- Enrollment
- 274 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2028
- U.S. locations
- 23
- States / cities
- Duarte, California • Sacramento, California • Chicago, Illinois + 17 more
- Conditions
- Healthy Volunteers
- Interventions
- C16TR, Placebo, Tyvaso®
- Drug
- Lead sponsor
- Insmed Incorporated
- Industry
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Pharmacokinetics, Safety, Tolerability
- Interventions
- 5-methoxy-N,N-dimethyltryptamine succinate salt, Placebo
- Drug
- Lead sponsor
- Usona Institute
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 54 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Overland Park, Kansas
- Conditions
- Friedreich's Ataxia
- Interventions
- Low dose cohort, High dose cohort
- Drug
- Lead sponsor
- Biojiva LLC
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 2
- States / cities
- Long Beach, California • Tampa, Florida
- Conditions
- Advanced Solid Tumor
- Interventions
- paclitaxel, TAK-228, TAK-117
- Drug
- Lead sponsor
- Avera McKennan Hospital & University Health Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 1
- States / cities
- Sioux Falls, South Dakota
- Conditions
- Chronic Hepatitis C
- Interventions
- ANA598 200 mg bid or placebo, ANA598 400 mg bid or placebo, ANA598 800 mg bid or placebo
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 3
- States / cities
- St Louis, Missouri • New York, New York • San Antonio, Texas
- Conditions
- NMDAR Autoimmune Encephalitis, LGI1 Autoimmune Encephalitis
- Interventions
- Satralizumab, Placebo
- Drug · Other
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 122 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 11
- States / cities
- Birmingham, Alabama • Newport Beach, California • San Francisco, California + 7 more
- Conditions
- Social Isolation, Depression
- Interventions
- TERTULIAS structured dialogue peer support groups, Modified Attention Placebo Control (MAPC)
- Behavioral
- Lead sponsor
- University of New Mexico
- Other
- Eligibility
- 18 Years to 90 Years · Female only
- Enrollment
- 241 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2024
- U.S. locations
- 2
- States / cities
- Albuquerque, New Mexico
- Conditions
- Hodgkin Lymphoma
- Interventions
- doxorubicin, Bleomycin, vinblastine, dacarbazine, Nivolumab
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 82 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2027
- U.S. locations
- 9
- States / cities
- Detroit, Michigan • Basking Ridge, New Jersey • Hackensack, New Jersey + 6 more
- Conditions
- Glaucoma
- Interventions
- Optical Coherence Tomography
- Diagnostic Test
- Lead sponsor
- Twin Cities Eye Consultants
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 141 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Coon Rapids, Minnesota
- Conditions
- Acne Inversa
- Interventions
- PF-06650833, PF-06700841, PF-06826647, Placebo
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 194 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 63
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Fremont, California + 42 more
- Conditions
- Dual Sensory Impairment of Vision and Hearing
- Interventions
- SuperEar9000
- Device
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 60 Years and older
- Enrollment
- 168 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Neoplasms
- Interventions
- GSK3174998, Pembrolizumab
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 141 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2020
- U.S. locations
- 5
- States / cities
- Boston, Massachusetts • New York, New York • Nashville, Tennessee + 1 more
- Conditions
- SCC - Squamous Cell Carcinoma, Radiotracer, Head and Neck Squamous Cell Carcinoma, Metastatic Head and Neck Squamous Cell Carcinoma
- Interventions
- Cetuximab (EGFR inhibitor), 18F-NOTA-ABY-030, Positron Emission Tomography (PET)
- Drug · Procedure
- Lead sponsor
- Vanderbilt-Ingram Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Acute Kidney Injury
- Interventions
- Blood sample
- Procedure
- Lead sponsor
- Avera McKennan Hospital & University Health Center
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 1
- States / cities
- Sioux Falls, South Dakota